PMC:7274950 / 8751-9302 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T123","span":{"begin":130,"end":151},"obj":"CHEBI:37395;CHEBI:37395"},{"id":"T124","span":{"begin":280,"end":284},"obj":"UBERON:0000165"},{"id":"T125","span":{"begin":366,"end":370},"obj":"UBERON:0000165"},{"id":"T47035","span":{"begin":130,"end":151},"obj":"CHEBI:37395;CHEBI:37395"},{"id":"T27552","span":{"begin":280,"end":284},"obj":"UBERON:0000165"},{"id":"T33735","span":{"begin":366,"end":370},"obj":"UBERON:0000165"}],"text":"Sechi et al. [25] recently reported their experience with 102 patients affected by the following diseases: Gaucher, Pompe, Fabry, mucopolysaccharidosis, Niemann Pick type C and cystinosis. At the beginning of the pandemic, 71 pt. (69.6%) were receiving ERT and 26 (25.5%) were on oral treatments. No interruption or modification occurred for patients receiving only oral therapy. All patients who were already on home-therapy continued their ERT infusions regularly, but 49% of patients receiving ERT in the hospital experienced treatment disruptions."}

{"project":"LitCovid-PubTator","denotations":[{"id":"227","span":{"begin":62,"end":70},"obj":"Species"},{"id":"228","span":{"begin":342,"end":350},"obj":"Species"},{"id":"229","span":{"begin":384,"end":392},"obj":"Species"},{"id":"230","span":{"begin":478,"end":486},"obj":"Species"},{"id":"231","span":{"begin":177,"end":187},"obj":"Disease"}],"attributes":[{"id":"A227","pred":"tao:has_database_id","subj":"227","obj":"Tax:9606"},{"id":"A228","pred":"tao:has_database_id","subj":"228","obj":"Tax:9606"},{"id":"A229","pred":"tao:has_database_id","subj":"229","obj":"Tax:9606"},{"id":"A230","pred":"tao:has_database_id","subj":"230","obj":"Tax:9606"},{"id":"A231","pred":"tao:has_database_id","subj":"231","obj":"MESH:D003554"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Sechi et al. [25] recently reported their experience with 102 patients affected by the following diseases: Gaucher, Pompe, Fabry, mucopolysaccharidosis, Niemann Pick type C and cystinosis. At the beginning of the pandemic, 71 pt. (69.6%) were receiving ERT and 26 (25.5%) were on oral treatments. No interruption or modification occurred for patients receiving only oral therapy. All patients who were already on home-therapy continued their ERT infusions regularly, but 49% of patients receiving ERT in the hospital experienced treatment disruptions."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T52","span":{"begin":130,"end":151},"obj":"Disease"},{"id":"T53","span":{"begin":177,"end":187},"obj":"Disease"}],"attributes":[{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0019249"},{"id":"A53","pred":"mondo_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/MONDO_0016239"}],"text":"Sechi et al. [25] recently reported their experience with 102 patients affected by the following diseases: Gaucher, Pompe, Fabry, mucopolysaccharidosis, Niemann Pick type C and cystinosis. At the beginning of the pandemic, 71 pt. (69.6%) were receiving ERT and 26 (25.5%) were on oral treatments. No interruption or modification occurred for patients receiving only oral therapy. All patients who were already on home-therapy continued their ERT infusions regularly, but 49% of patients receiving ERT in the hospital experienced treatment disruptions."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T106","span":{"begin":58,"end":61},"obj":"http://purl.obolibrary.org/obo/CLO_0054060"},{"id":"T107","span":{"begin":223,"end":225},"obj":"http://purl.obolibrary.org/obo/CLO_0054055"}],"text":"Sechi et al. [25] recently reported their experience with 102 patients affected by the following diseases: Gaucher, Pompe, Fabry, mucopolysaccharidosis, Niemann Pick type C and cystinosis. At the beginning of the pandemic, 71 pt. (69.6%) were receiving ERT and 26 (25.5%) were on oral treatments. No interruption or modification occurred for patients receiving only oral therapy. All patients who were already on home-therapy continued their ERT infusions regularly, but 49% of patients receiving ERT in the hospital experienced treatment disruptions."}

{"project":"LitCovid-sentences","denotations":[{"id":"T63","span":{"begin":0,"end":106},"obj":"Sentence"},{"id":"T64","span":{"begin":107,"end":188},"obj":"Sentence"},{"id":"T65","span":{"begin":189,"end":296},"obj":"Sentence"},{"id":"T66","span":{"begin":297,"end":379},"obj":"Sentence"},{"id":"T67","span":{"begin":380,"end":551},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Sechi et al. [25] recently reported their experience with 102 patients affected by the following diseases: Gaucher, Pompe, Fabry, mucopolysaccharidosis, Niemann Pick type C and cystinosis. At the beginning of the pandemic, 71 pt. (69.6%) were receiving ERT and 26 (25.5%) were on oral treatments. No interruption or modification occurred for patients receiving only oral therapy. All patients who were already on home-therapy continued their ERT infusions regularly, but 49% of patients receiving ERT in the hospital experienced treatment disruptions."}